Abstract:The prevalence of ocular chronic diseases, like those associated to diabetes (diabetic retinopathy, macular edema and glaucoma), has increased significantly in the last years. They affect quite negatively people's quality of life, leading to extremely high economic costs both for patients and society. Recent advances in pharmacotherapy have greatly improved their prognosis. However, the efficacy and safety of the treatments currently available are still a concern. Topical drug delivery (DD) is useful to treat diseases of the anterior segment of the eye, but new strategies are needed to increase drug's bioavailability, which is quite low, and to overcome the difficulties that e.g. elderly people face in topical administration. Regarding the posterior segment, the challenge is to reach the target tissues due to the eye's natural barriers. Topical treatments are generally useless in this case. Systemic administration requires large doses to achieve local therapeutic levels and may induce undesirable side effects. Intravitreal route provides direct access to the intraocular environment and is highly effective, but is rather invasive and may origin serious complications, such as endophthalmitis, retinal detachment, intravitreal haemorrhage and cataract. In BioMat Research Group of IST, and within the frame of ORBITAL and SOL projects, we are making efforts to develop and optimize new DD systems for the treatment of diabetic ocular diseases that use noninvasive routes and present sustained drug release capabilities, increasing the drug's bioavailability at the target tissues. We propose the use of soft contact lenses (SCLs) as DD vehicles, due to their high biocompatibility and prolonged contact with the eye. Being frequently replaced, SCLs may be used as drug reservoirs for continued treatments, not only of diseases of the anterior part of the eye, but also of the posterior, using innovative techniques that enhance the drug penetration in the eye. Although in the last years much research has been done on this type of devices, they are still not available in the market due to a number of reasons, such as the need of improving systems efficiency, the difficulty in transposing to industry the preparation methodologies, issues related with sterilization/storage or lack of in vivo and clinical tests. In our studies, we have used different strategies to increase the bioavailability of the drugs and achieve adequate drug release profiles. Besides applying coatings and molecular imprinting techniques, we investigated the formation of prodrugs and drug inclusion in nanostructures that protect them in the biological medium. The incorporation in SCLs of cell penetrating peptides (CPP) that increase drug's ability to cross the corneal epithelium and reach the back of the eye, also led to to promising results. Ex‐vivo tests and mathematical modelling were used to predict the biological performance of the drug‐loaded devices in vivo before performing tests with animal models. Finally, alternative sterilization techniques which allow to process such challenging systems were explored.The obtained results shall contribute for the development of new forms of treatment of ocular diseases that are more predictable, safe and effective, giving response to an unmet clinical need.

Depot unilamellar liposomes to sustain transscleral drug Co-delivery for ophthalmic infection therapy

Design of liposomal nanocarriers with a potential for combined dexamethasone and bevacizumab delivery to the eye

Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery

Cyclosporine-loaded micelles for ocular delivery: Investigating the penetration mechanisms

In-situ tear fluid dissolving nanofibers enable prolonged viscosity-enhanced dual drug delivery to the eye

Dendritic Oligoethylenimine Decorated Liposome with Augmented Corneal Retention and Permeation for Efficient Topical Delivery of Antiglaucoma Drugs

Novel mPEG-CS-modified flexible liposomes-reinforced thermosensitive sol-gel reversible hydrogels for ocular delivery of multiple drugs with enhanced synergism

Liposomal dexamethasone–moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing

Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation

In vitro and in vivo assessment of structural integrity for HPCD complex@Liposome nanocomposites from ocular surface to the posterior segment of the eye

Enhanced Ocular Drug Delivery of Dexamethasone Using a Chitosan-Coated Soluplus®-Based Mixed Micellar System

Lipo-PEG nano-ocular formulation successfully encapsulates hydrophilic fluconazole and traverses corneal and non-corneal path to reach posterior eye segment

Drug‐delivery contact lenses

Chondroitin sulfate and L-Cysteine conjugate modified cationic nanostructured lipid carriers: Pre-corneal retention, permeability, and related studies for dry eye treatment

A Sustainable Retinal Drug Codelivery for Boosting Therapeutic Efficacy in wAMD: Unveiling Multifaceted Evidence and Synergistic Mechanisms

Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application

Liposome‐Based Permeable Eyedrops for Effective Posterior Segment Drug Delivery

An intravitreal-injectable hydrogel depot doped borneol-decorated dual-drug-coloaded microemulsions for long-lasting retina delivery and synergistic therapy of wAMD

Thiolated Nanostructured Lipid Carriers As a Potential Ocular Drug Delivery System for Cyclosporine A: Improving in Vivo Ocular Distribution.